Hyperfine Inc (HYPR)

Official site

HEALTHCARE • MEDICAL DEVICES • NASDAQ

$0.80

-0.05 (-6.04%)

Market Cap: $90.30M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

78%(14/18)

Avg Surprise

-2.95%

Streak

3 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.08

Range$-0.08 - $-0.08

2 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.09+11.1%

60d ago$-0.080.0%

30d ago$-0.080.0%

7d ago$-0.080.0%

Current$-0.08

Revenue Consensus

$5M

Range$5M - $6M

3 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.08

Range$-0.08 - $-0.08

2 analysts

Revenue Consensus

$7M

Range$7M - $7M

3 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.08	$-0.08 - $-0.08	-	-	2	-	-
Sep 30, 2026Sep 26EST	-	$-0.08	$-0.08 - $-0.08	-	-	2	2 0 30d	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$-0.09	$-0.09	$-0.09 - $-0.09	+0.00%	Beat	2	No revisions (30d)	+25.0%
Mar 31, 2026Mar 26 Reported May 12, 2026Reported May 12	$-0.09	$-0.11	$-0.11 - $-0.11	+19.73%	Beat	2	No revisions (30d)	+26.4%
Dec 31, 2025Dec 25 Reported Mar 18, 2026Reported Mar 18	$-0.08	$-0.08	$-0.08 - $-0.08	+0.00%	Beat	2	1 0 30d	+42.9%
Sep 30, 2025Sep 25 Reported Nov 13, 2025Reported Nov 13	$-0.14	$-0.10	$-0.11 - $-0.10	-40.00%	Miss	2	1 0 30d	+0.0%
Jun 30, 2025Jun 25 Reported Aug 13, 2025Reported Aug 13	$-0.12	$-0.12	$-0.12 - $-0.12	+0.00%	Beat	3	0 2 30d	+14.3%
Mar 31, 2025Mar 25 Reported May 13, 2025Reported May 13	$-0.12	$-0.12	$-0.12 - $-0.11	+0.00%	Beat	4	No revisions (30d)	+14.3%
Dec 31, 2024Dec 24 Reported Mar 17, 2025Reported Mar 17	$-0.14	$-0.14	$-0.15 - $-0.12	+0.00%	Beat	2	No revisions (30d)	+6.7%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-0.14	$-0.14	$-0.14 - $-0.14	+0.00%	Beat	3	No revisions (30d)	+6.7%
Jun 30, 2024Jun 24 Reported Aug 8, 2024Reported Aug 8	$-0.14	$-0.14	$-0.15 - $-0.13	+0.00%	Beat	3	No revisions (30d)	+6.7%
Mar 31, 2024Mar 24 Reported May 13, 2024Reported May 13	$-0.14	$-0.15	$-0.16 - $-0.14	+6.67%	Beat	3	No revisions (30d)	+17.6%
Dec 31, 2023Dec 23 Reported Mar 21, 2024Reported Mar 21	$-0.15	$-0.18	$-0.20 - $-0.16	+16.67%	Beat	3	No revisions (30d)	+21.1%
Sep 30, 2023Sep 23 Reported Nov 9, 2023Reported Nov 9	$-0.15	$-0.16	$-0.17 - $-0.15	+6.25%	Beat	2	No revisions (30d)	+21.1%
Jun 30, 2023Jun 23 Reported Aug 14, 2023Reported Aug 14	$-0.15	$-0.16	$-0.17 - $-0.16	+6.25%	Beat	2	No revisions (30d)	+54.5%
Mar 31, 2023Mar 23 Reported May 11, 2023Reported May 11	$-0.17	$-0.13	$-0.16 - $-0.11	-30.77%	Miss	3	No revisions (30d)	+50.0%
Dec 31, 2022Dec 22 Reported Mar 21, 2023Reported Mar 21	$-0.19	$-0.25	$-0.25 - $-0.20	+24.00%	Beat	3	No revisions (30d)	+48.6%
Sep 30, 2022Sep 22 Reported Nov 10, 2022Reported Nov 10	$-0.19	$-0.26	$-0.26 - $-0.25	+26.92%	Beat	3	No revisions (30d)	-533.3%
Jun 30, 2022Jun 22 Reported Aug 10, 2022Reported Aug 10	$-0.33	$-0.26	$-0.26 - $-0.26	-26.92%	Miss	1	No revisions (30d)	-560.0%
Mar 31, 2022Mar 22 Reported May 11, 2022Reported May 11	$-0.34	$-0.21	$-0.21 - $-0.21	-61.90%	Miss	1	No revisions (30d)	-3300.0%
Dec 31, 2021Dec 21 Reported Mar 23, 2022Reported Mar 23	$-0.37	N/A	-	N/A	Beat	-	-	-
Sep 30, 2021Sep 21 Reported Nov 18, 2021Reported Nov 18	$-0.03	N/A	-	N/A	Beat	-	-	-
Jun 30, 2021Jun 21 Reported Aug 18, 2021Reported Aug 18	$-0.05	N/A	-	N/A	Beat	-	-	-
Mar 31, 2021Mar 21 Reported May 17, 2021Reported May 17	$-0.01	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-2.01	EV/EBITDA	N/A
Price/FCF	-2.90x	FCF Yield	-34.48%
Profitability
Profit Margin	-210.70%	Operating Margin	-216.90%
ROE	-97.00%	ROIC	-55.60%
Financial Health
Debt/Equity	0.36x	Interest Coverage	N/A
Current Ratio	6.15x	Quick Ratio	5.45x
Trading Statistics
Beta	1.46	Avg Volume	1.16M
52-Week High	$1.94	52-Week Low	$0.75

Technical Indicators Dashboard

Moving Averages

SMA 10$0.88

SMA 20$0.84

SMA 50$0.85

SMA 200$1.15

EMA 10$0.86

EMA 20$0.85

EMA 50$0.89

EMA 200$1.07

MACD

Line: 0.01Signal: 0.00Hist: 0.00

ADX

ADX: 35.3+DI: 25.9-DI: 19.2

Aroon & PSAR

Aroon Up88.0

Aroon Down32.0

PSAR$1.05

Bollinger Bands

Upper Band$0.94

Lower Band$0.74

%B Position2463%(Upper)

Band Width0.31

RSI (14-Day)

Neutral

42.3

Momentum Oscillators

Stoch %K26.9

Stoch %D44.6

Williams %R-97.2

ROC (10d)-1.0%

Momentum-0.01

CCI (20d)-36.8

MFI (14d)80.0

Volatility Measures

ATR (14d)$0.06(8.1%)

StdDev (20d)0.05

Hist Vol64.7%(High)

Volume Flow

VWAP$0.82

OBV82.6M

AD Line-35.6M

CMF (20d)-0.022

Volume Metrics

Avg Vol (20d)1.2M

Vol Ratio0.6x

VWMA (20d)$0.89

Pivot Points

R3$0.94

R2$0.92

R1$0.88

Pivot Point$0.87

S1$0.83

S2$0.82

S3$0.78

Advanced Oscillators

TSI4.60

Ultimate Osc31.4

KST55.40

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$3.90M	$3.90M	$5.29M	$3.44M	$2.70M	$2.14M	$2.32M	$3.64M	$3.63M	$3.29M	$2.69M	$2.33M
Cost of Revenue	$1.92M	$1.92M	$2.60M	$1.59M	$1.37M	$1.25M	$1.50M	$1.74M	$1.83M	$1.94M	$1.65M	$1.21M
Gross Profit	$1.98M	$1.98M	$2.69M	$1.85M	$1.33M	$883,000	$826,000	$1.91M	$1.80M	$1.35M	$1.03M	$1.12M

Operating Expenses	$10.45M	$10.54M	$10.36M	$10.77M	$10.92M	$11.79M	$11.59M	$12.87M	$12.65M	$12.00M	$12.66M	$12.88M
R&D	$3.87M	$3.85M	$3.83M	$4.05M	$4.54M	$5.04M	$5.11M	$5.87M	$5.96M	$5.57M	$5.96M	$5.74M
SG&A	$3.91M	$4.13M	$4.03M	$4.15M	$3.86M	$4.21M	$4.13M	$4.51M	$4.42M	$4.43M	$4.17M	$4.62M
Operating Income	$-8,469,000	$-8,558,000	$-7,668,000	$-8,920,000	$-9,595,000	$-10,902,000	$-10,765,000	$-10,963,000	$-10,846,000	$-10,650,000	$-11,629,000	$-11,759,000

Interest Income	$272,000	$254,000	$280,000	$187,000	$239,000	$317,000	$436,000	$585,000	$675,000	$796,000	$922,000	$1.02M
Interest Expense	$533,000	$83,000	$0	$2.10M	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-9,298,000	$-8,623,000	$-5,912,000	$-11,019,000	$-9,225,000	$-9,418,000	$-10,390,000	$-10,326,000	$-10,156,000	$-9,848,000	$-10,684,000	$-10,757,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-9,298,000	$-8,623,000	$-5,912,000	$-11,019,000	$-9,225,000	$-9,418,000	$-10,390,000	$-10,326,000	$-10,156,000	$-9,848,000	$-10,684,000	$-10,757,000

EBITDA	$-8,661,000	$-8,503,000	$-5,865,000	$-10,909,000	$-9,181,000	$-9,506,000	$-10,592,000	$-10,652,000	$-10,578,000	$-10,381,000	$-11,343,000	$-11,500,000
EBIT	$-9,037,000	$-8,794,000	$-6,146,000	$-11,206,000	$-9,464,000	$-9,735,000	$-10,826,000	$-10,911,000	$-10,831,000	$-10,644,000	$-11,606,000	$-11,778,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about HYPR

News

Preliminary Q3 revenue rises 55% year over year at Hyperfine (HYPR), topping net cash burn for the first time.

Hyperfine (HYPR) announced preliminary, unaudited Q3 2026 revenue of approximately $6.0 million, representing a 55% year-over-year increase and a 53% sequential increase. For the first time...

Stock Titan•Oct 8, 2026 9:10 AM ET10/8/26•Bullish

HYPR | Hyperfine, Inc. Class A Financials - Revenue Breakdown

This article provides a financial overview of Hyperfine, Inc. (HYPR), focusing on its revenue breakdown, government contracts, and other financial metrics. It details the company's business model...

Quiver Quantitative•Aug 23, 2026 11:17 AM ET8/23/26•Neutral

Hyperfine Q2 2026 earnings: Revenue rises 45% as operating loss narrows

Hyperfine (Nasdaq: HYPR) reported a 44.8% increase in Q2 2026 revenue, reaching $3.904 million, with commercial Swoop system sales rising and gross margin expanding...

TradingKey•Aug 6, 2026 4:41 PM ET8/6/26•Neutral

Hyperfine (Nasdaq: HYPR) grows Q2 2026 revenue 44.8% as cash rises to $43.5M

Hyperfine, Inc. reported a significant 44.8% increase in Q2 2026 revenue, reaching $3.9 million, with cash and cash equivalents growing to $43.5 million. The company also announced CE Mark and UKCA approvals...

Stock Titan•Aug 6, 2026 3:40 PM ET8/6/26•Somewhat-Bullish

OrthoPediatrics ( KIDS ) Reports Q2 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of +16.13% and +3.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks Commentary•Aug 4, 2026 7:00 PM ET8/4/26•Neutral

HYPR Valuation and Fair Value

P/E: -2.0x
P/FCF: -2.9x
P/B: 2.2x

See GNG's fair value

HYPR Profitability: Margins, ROIC and FCF

Gross margin: 51.4%
Operating margin: -216.9%
Net margin: -210.7%
ROIC: -55.6%
ROE: -97.0%
FCF margin: -166.5%
FCF yield: -34.5%

HYPR Competitors

Company	Ticker
Immunic Inc	IMUX
Rallybio Corp	RLYB
Biomea Fusion Inc	BMEA
Forian Inc	FORA
OnKure Therapeutics, Inc.	OKUR
Equillium Inc	EQ
Insight Molecular Diagnostics Inc.	IMDX
Neuraxis, Inc.	NRXS

Sector: Healthcare

HYPR Analyst Ratings

Consensus: Buy
Analysts: 3
Strong Buy: 0
Buy: 3
Hold: 0
Sell: 0
Strong Sell: 0

HYPR Bull Case vs Bear Case

Bull case

HYPR grew quarterly revenue 44.8% year over year.

Bear case

HYPR has a -210.7% net profit margin.
HYPR beat EPS estimates in 12.5% of its last 8 reported quarters.

HYPR Earnings: Beat Rate and Next Report

Beat rate: 1 of 8 quarters (12.5%)
Average surprise: -2.5%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.08
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 2 up, 0 down

Frequently Asked Questions About HYPR

Does HYPR pay dividends?

Hyperfine Inc (HYPR) does not currently pay a regular dividend.

What is HYPR's market cap?

Hyperfine Inc (HYPR) has a market capitalization of $90.30M with a current stock price of $0.80.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In